Jazz Pharmaceuticals Gestione
Criteri Gestione verificati 3/4
Jazz Pharmaceuticals Il CEO è Renee Gala, nominato in Oct2023, e ha un mandato di 2.67 anni. la retribuzione annua totale è $ 19.15M, composta da 5.2% di stipendio e 94.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.074% delle azioni della società, per un valore di $ 10.79M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.8 anni e 10.2 anni.
Informazioni chiave
Renee Gala
Amministratore delegato
US$19.2m
Compenso totale
| Percentuale dello stipendio del CEO | 5.24% |
| Mandato del CEO | 2.7yrs |
| Proprietà del CEO | 0.07% |
| Durata media del management | 6.8yrs |
| Durata media del Consiglio di amministrazione | 10.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Jun 06
JAZZ: Oncology Readouts And CNS Durability Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Jazz Pharmaceuticals to $304.19 from $263.59, citing higher modeled revenue growth, stronger profit margins supported by views on Ziihera and zanidatamab, and confidence in Xywav patent protections that they argue could justify a modestly lower future P/E multiple. Analyst Commentary Recent Street research on Jazz Pharmaceuticals presents a mixed but generally constructive tone, with several bullish analysts pointing to patent clarity on Xywav and the commercial opportunity for Ziihera and zanidatamab as key support pillars for their models.
Aggiornamento della narrazione • May 23
JAZZ: Oncology Execution Risks Will Drive Future Multiple Compression Concerns
Analysts have lifted the fair value estimate for Jazz Pharmaceuticals from $188.00 to about $200.51, citing a higher assumed future P/E multiple. They link this to growing confidence in the broader Ziihera and zanidatamab opportunities, even as they factor in slightly lower long term profit margins and ongoing competitive pressure on legacy neurology drugs.Articolo di analisi • May 13
We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings
The market was pleased with the recent earnings report from Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ), despite the...Articolo di analisi • May 08
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) investors will be delighted, with the company turning in some strong numbers...
Aggiornamento della narrazione • Apr 28
JAZZ: HER2 GEA Data Will Support Future Oncology Leadership Thesis
Analysts have nudged the price target on Jazz Pharmaceuticals higher to about $226, reflecting updated views on margins, central nervous system revenue durability, and upcoming oncology contributions following recent Q4 results and refreshed models. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has centered on refreshed models following Q4 results, updated revenue guidance, and the expected contribution from oncology assets alongside the core central nervous system portfolio.Aggiornamento della narrazione • Apr 13
JAZZ: CNS Cash Flows And Upcoming Oncology Launches Will Shape Execution Risks
Analysts have increased their average price target on Jazz Pharmaceuticals by $13 to $255, citing more supportive assumptions around revenue growth, profit margins and a slightly lower future P/E following the recent Q4 results and updated guidance. Analyst Commentary Recent research on Jazz Pharmaceuticals has largely centered on updated price targets and ratings following the company’s Q4 report and new guidance.Aggiornamento della narrazione • Mar 30
JAZZ: CNS Cash Flows And HER2 Franchise Will Shape Oncology Execution Risks
Narrative Update on Jazz Pharmaceuticals Analysts have lifted price targets on Jazz Pharmaceuticals by roughly $10 to $45 into a $224 to $275 range, citing steady central nervous system demand, updated Ziihera and zanidatamab expectations following HERIZON-GEA data, and recent Q4 results that aligned with or modestly exceeded prior forecasts. Analyst Commentary Recent research on Jazz Pharmaceuticals has been broadly constructive, with several firms adjusting price targets higher after Q4 results and the HERIZON GEA data updates.Aggiornamento della narrazione • Mar 16
JAZZ: HER2 Data And CNS Cash Flows Will Balance Oncology Execution Risks
The analyst price target for Jazz Pharmaceuticals has been adjusted slightly higher to reflect a $1 increase in fair value to $188, lower modeled revenue growth at 2.92%, a higher profit margin assumption at 21.90%, and a reduced future P/E of 13.95, as analysts point to a resilient central nervous system franchise, updated views on Ziihera and zanidatamab opportunities, and recent Q4 results and guidance. Analyst Commentary Recent research coverage points to generally constructive sentiment on Jazz Pharmaceuticals, with a cluster of higher price targets anchored to the company’s central nervous system portfolio and oncology pipeline, including Ziihera and zanidatamab.Aggiornamento della narrazione • Mar 02
JAZZ: Oncology Readouts And CNS Durability Will Drive Future Upside Potential
Our analyst fair value estimate for Jazz Pharmaceuticals has moved from $230.00 to about $263.59, as analysts factor in stronger margin expectations, a slightly higher discount rate, and ongoing Street enthusiasm around Ziihera and the broader oncology pipeline following recent Q4 updates and HERIZON-GEA data presentations. Analyst Commentary Recent Street research has leaned constructive on Jazz Pharmaceuticals, with multiple bullish analysts revisiting their models following Q4 results and the latest HERIZON-GEA data.Seeking Alpha • Feb 26
Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook
Summary Jazz Pharmaceuticals is positioned for long-term value creation, with a relief rally following Q4 2025 results and 2026 outlook for the oxybate business. Jazz expects Xywav revenues to be flat or up mid-single digits in 2026, despite generic Xyrem headwinds, with the oxybate franchise revenues projected at $1.8-1.9 billion. Strong Modeyso launch and robust Ziihera phase 3 data in first-line GEA set up new growth drivers, with Ziihera's U.S. launch anticipated in 2H 2026. Multiple expansion and valuation re-rating are possible as investors look past widespread availability of Xyrem generics, with Ziihera and other assets supporting (at least) mid-single-digit revenue growth. Read the full article on Seeking AlphaAggiornamento della narrazione • Feb 16
JAZZ: HER2 Practice-Changing GEA Data Will Drive Future Oncology Leadership
Narrative Update Overview The analyst price target for Jazz Pharmaceuticals has moved higher, with our fair value estimate rising from $213 to $219.40 as analysts factor in stronger Ziihera and zanidatamab potential, supported by recent HERIZON-GEA data and updated Street research. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has been largely constructive, with multiple firms updating their work after the detailed HERIZON-GEA-01 readout and related discussions around Ziihera and zanidatamab.Aggiornamento della narrazione • Feb 02
JAZZ: Practice-Changing HER2 Data Will Drive Oncology Upside And Rebalance Legacy Risks
Analysts have raised their price targets on Jazz Pharmaceuticals by approximately $10 to $30 per share, citing what they describe as practice-changing HERIZON GEA data for Ziihera and a clearer oncology pipeline driver as key supports for the higher valuations. Analyst Commentary Across recent research notes, analysts have been revising their views on Jazz Pharmaceuticals primarily around the HERIZON GEA data for Ziihera and what it could mean for the oncology portfolio.Aggiornamento della narrazione • Jan 19
JAZZ: Practice-Changing HER2 Data Will Rebalance Oncology Potential And Legacy Risks
Jazz Pharmaceuticals' updated analyst price target has edged down by US$1 to US$187 as analysts factor in slightly higher growth and margin assumptions, supported by recent HERIZON-GEA-01 data that they describe as practice changing for Ziihera and potentially supportive of new standard-of-care use across several HER2+ cancer settings. Analyst Commentary Across recent research, most firms are reacting to the HERIZON-GEA-01 data by lifting their Jazz Pharmaceuticals price targets and highlighting Ziihera and zanidatamab as key value drivers.Aggiornamento della narrazione • Jan 05
JAZZ: Oncology Data Will Reshape Revenue Mix While Legacy Headwinds Persist
We are raising our Jazz Pharmaceuticals fair value estimate to $188 from $147 as analysts boost price targets following positive HERIZON-GEA-01 data for Ziihera, which they see as a potential new standard of care and a multibillion dollar revenue driver. Analyst Commentary Street research following the HERIZON-GEA-01 topline readout has turned broadly constructive on Jazz Pharmaceuticals, with multiple firms lifting price targets and reiterating positive ratings.Aggiornamento della narrazione • Dec 18
JAZZ: HER2-Positive GEA Breakthrough Will Drive Future Oncology Leadership
Analysts have nudged their fair value estimate for Jazz Pharmaceuticals higher to $213.00 from $208.50, reflecting stronger long term revenue growth expectations and a richer future P/E multiple, supported by increasingly bullish views on Ziihera's potential to become a new standard of care in HER2 positive GEA and a key oncology growth driver. Analyst Commentary Bullish analysts are largely focused on the upside from Ziihera's HERIZON-GEA-01 data, with multiple research shops lifting price targets and embedding higher long term oncology growth into their models.Aggiornamento della narrazione • Dec 04
JAZZ: HER2-Positive GEA Success Will Drive Future Oncology Leadership And Upside
Our fair value estimate for Jazz Pharmaceuticals has nudged higher to $208.50 from $206.38, reflecting analysts' upward revisions to price targets as they factor in expectations of stronger long term revenue growth and profitability. This is driven by Ziihera's potential as a new standard of care in HER2 positive GEA and broader oncology indications.Aggiornamento della narrazione • Nov 20
JAZZ: Recent Positive Trial Data Will Drive Future Leadership In HER2-Positive Oncology
Analysts have increased their price target for Jazz Pharmaceuticals from approximately $186 to $206 per share. They cite improved revenue growth projections and recent strong clinical data supporting the potential of Ziihera as a standard-of-care therapy in HER2-positive cancers.Articolo di analisi • Nov 18
Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified
Despite an already strong run, Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) shares have been powering on, with a gain of...Aggiornamento della narrazione • Aug 30
Emerging Therapies And Portfolio Expansion Will Shape Future Markets
Analysts have modestly raised their price targets for Jazz Pharmaceuticals, driven by growing confidence in Modeyso's commercial prospects and expanded market potential, partially offset by persistent challenges in other segments, resulting in a new consensus target of $186.47. Analyst Commentary Bullish analysts are increasingly positive on the commercial potential of Modeyso following its recent approval, citing higher-than-expected pricing, a dedicated launch strategy, and strong patient/prescriber interest.Articolo di analisi • Aug 09
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Last week, you might have seen that Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) released its second-quarter result to the...Articolo di analisi • Jul 21
Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E
With a price-to-earnings (or "P/E") ratio of 14.2x Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) may be sending bullish...Articolo di analisi • Jul 03
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Dec 23
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Summary Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven by zanidatamab's approval and other key drugs like Rylaze and Zepzelca, crucial for achieving Vision 2025 sales goals. An updated analysis around Jazz Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$29m |
| Dec 31 2025 | US$19m | US$1m | -US$356m |
| Sep 30 2025 | n/a | n/a | -US$368m |
| Jun 30 2025 | n/a | n/a | -US$405m |
| Mar 31 2025 | n/a | n/a | US$482m |
| Dec 31 2024 | US$7m | US$825k | US$560m |
| Sep 30 2024 | n/a | n/a | US$463m |
| Jun 30 2024 | n/a | n/a | US$395m |
| Mar 31 2024 | n/a | n/a | US$331m |
| Dec 31 2023 | US$5m | US$768k | US$415m |
| Sep 30 2023 | n/a | n/a | US$80m |
| Jun 30 2023 | n/a | n/a | -US$87m |
| Mar 31 2023 | n/a | n/a | -US$156m |
| Dec 31 2022 | US$5m | US$690k | -US$224m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$52m |
| Mar 31 2022 | n/a | n/a | -US$450m |
| Dec 31 2021 | US$5m | US$617k | -US$330m |
| Sep 30 2021 | n/a | n/a | -US$161m |
| Jun 30 2021 | n/a | n/a | US$40m |
| Mar 31 2021 | n/a | n/a | US$518m |
| Dec 31 2020 | US$4m | US$485k | US$239m |
Compensazione vs Mercato: La retribuzione totale di Renee ($USD 19.15M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 14.81M ).
Compensazione vs guadagni: La retribuzione di Renee è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Renee Gala (54 yo)
2.7yrs
Mandato
US$19,151,558
Compensazione
Ms. Renée D. Galá is an Independent Director of DexCom, Inc. from March 6, 2025. She serves as President at Jazz Pharmaceuticals plc since October 2023 and served as Chief Operating Officer at Jazz Pharmac...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Chairman | 23.4yrs | US$15.32m | 0.53% $ 77.6m | |
| President | 2.7yrs | US$19.15m | 0.074% $ 10.8m | |
| Executive VP & CFO | 2.3yrs | US$7.54m | 0.033% $ 4.8m | |
| Executive VP & Chief Legal Officer | 6.9yrs | US$6.30m | 0.030% $ 4.4m | |
| Executive VP | 7.1yrs | US$8.61m | 0.064% $ 9.4m | |
| Executive VP & Chief Commercial Officer | 6.3yrs | US$6.08m | 0.027% $ 3.9m | |
| Senior VP & Chief Accounting Officer | 6.8yrs | US$1.45m | Nessun dato | |
| Head of Investor Relations | no data | Nessun dato | Nessun dato | |
| Executive VP & Chief People Officer | 7.6yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Sleep & CNS Medicine | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Corporate Strategy | 6.8yrs | Nessun dato | Nessun dato | |
| Senior Vice President & Chief Transformation Officer | less than a year | Nessun dato | Nessun dato |
6.8yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di JAZZ è esperto e expertise (durata media dell'incarico 6.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Chairman | 23.4yrs | US$15.32m | 0.53% $ 77.6m | |
| President | less than a year | US$19.15m | 0.074% $ 10.8m | |
| Independent Director | 14.4yrs | US$500.56k | 2.04% $ 297.3m | |
| Independent Director | 13.1yrs | US$518.06k | 0.023% $ 3.3m | |
| Independent Director | 16.9yrs | US$495.56k | 0.028% $ 4.1m | |
| Independent Director | 2.3yrs | US$503.06k | 0.0051% $ 741.0k | |
| Lead Independent Director | 16.1yrs | US$555.56k | 0.0097% $ 1.4m | |
| Independent Non-Executive Director | 5.5yrs | US$520.56k | 0.012% $ 1.7m | |
| Independent Director | 1.9yrs | US$480.56k | 0.0055% $ 794.9k | |
| Independent Director | 13.1yrs | US$528.06k | 0.024% $ 3.5m | |
| Independent Non-Executive Director | 5.5yrs | US$490.56k | 0.012% $ 1.7m | |
| Independent Director | 7.3yrs | US$495.56k | 0.021% $ 3.0m |
10.2yrs
Durata media
63.5yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di JAZZ è composto da personale esperto e esperto (durata media dell'incarico 10.2 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/09 06:37 |
| Prezzo dell'azione a fine giornata | 2026/06/09 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Jazz Pharmaceuticals plc è coperta da 48 analisti. 18 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |